Accentia Biopharmaceuticals Inc – ‘10-K’ for 9/30/11 – ‘EX-21’

On:  Monday, 12/19/11, at 5:15pm ET   ·   For:  9/30/11   ·   Accession #:  1193125-11-345824   ·   File #:  0-51383

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.37M 
 2: EX-10.57    Royalty Termination Agreement                       HTML     26K 
 3: EX-10.58    Class 4 Plan Promissory Note                        HTML     33K 
 4: EX-10.59    Stock Pledge Agreement                              HTML     68K 
 5: EX-10.60    Asset Purchase Agreement                            HTML    314K 
 6: EX-10.61    Agreement                                           HTML     30K 
 7: EX-10.62    Loan Security Termination Agreement                 HTML     37K 
 8: EX-10.63    Loan Prepayment, Modification and Security          HTML     40K 
                Termination Agreement                                            
 9: EX-10.64    Amended and Restated Secured Term Note              HTML     58K 
10: EX-10.65    Amended and Restated Secured Term Note              HTML     58K 
11: EX-10.66    Amended and Restated Secured Term Note              HTML     58K 
12: EX-10.67    Amended and Restated Secured Term Note              HTML     58K 
13: EX-21       Subsidiaries of Accentia                            HTML     14K 
14: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
15: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
16: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
17: EX-32.2     Certification -- §906 - SOA'02                      HTML     16K 
36: R1          Document And Entity Information                     HTML     45K 
29: R2          Consolidated Balance Sheets                         HTML    182K 
34: R3          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
38: R4          Consolidated Statements Of Operations               HTML    129K 
49: R5          Consolidated Statements Of Stockholders' Deficit    HTML    123K 
30: R6          Consolidated Statements Of Cash Flows               HTML    216K 
33: R7          Company Overview And Summary Of Significant         HTML     84K 
                Accounting Policies                                              
27: R8          Liquidity And Management's Plans                    HTML    103K 
25: R9          Discontinued Operations                             HTML     52K 
50: R10         Inventories                                         HTML     25K 
40: R11         Unbilled Receivables And Unearned Revenues          HTML     32K 
39: R12         Intangible Assets                                   HTML     39K 
44: R13         Furniture, Equipment And Leasehold Improvements     HTML     31K 
45: R14         Reserve For Unresolved Claims                       HTML     18K 
43: R15         Note Payable                                        HTML     18K 
46: R16         Convertible Long-Term Debt                          HTML     98K 
35: R17         Other Long-Term Debt                                HTML     73K 
37: R18         Derivative Liabilities                              HTML     65K 
42: R19         Related Party Transactions                          HTML     51K 
53: R20         Liabilities Subject To Compromise                   HTML     35K 
47: R21         Income Taxes                                        HTML     55K 
31: R22         Stockholders' Equity                                HTML     98K 
41: R23         Employee Benefit Plan                               HTML     21K 
32: R24         Commitments And Contingencies                       HTML     59K 
24: R25         Variable Interest Entities                          HTML     27K 
48: R26         Pro Forma Results                                   HTML     21K 
51: R27         Subsequent Events                                   HTML     32K 
52: XML         IDEA XML File -- Filing Summary                      XML     56K 
26: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    698K 
18: EX-101.INS  XBRL Instance -- abpi-20110930                       XML    868K 
20: EX-101.CAL  XBRL Calculations -- abpi-20110930_cal               XML    158K 
21: EX-101.DEF  XBRL Definitions -- abpi-20110930_def                XML     62K 
22: EX-101.LAB  XBRL Labels -- abpi-20110930_lab                     XML    582K 
23: EX-101.PRE  XBRL Presentations -- abpi-20110930_pre              XML    353K 
19: EX-101.SCH  XBRL Schema -- abpi-20110930                         XSD     77K 
28: ZIP         XBRL Zipped Folder -- 0001193125-11-345824-xbrl      Zip    107K 

‘EX-21’   —   Subsidiaries of Accentia

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/14/12  SEC                               UPLOAD¶    10/20/17    1:47K  Accentia Biopharmaceuticals Inc.
 3/07/12  SEC                               UPLOAD¶    10/20/17    1:58K  Accentia Biopharmaceuticals Inc.